TRAP1-IN-1, identified by its CAS number 3031102-94-7, is a small molecule inhibitor that targets the mitochondrial chaperone TRAP1 (tumor necrosis factor receptor-associated protein 1). This compound is of interest in cancer research due to its potential role in modulating mitochondrial function and influencing cellular stress responses. TRAP1 is implicated in various cellular processes, including apoptosis and metabolism, making TRAP1-IN-1 a candidate for therapeutic applications in cancer treatment. The compound is characterized by its ability to selectively inhibit TRAP1 activity, which may lead to altered mitochondrial dynamics and enhanced sensitivity of cancer cells to chemotherapeutic agents. Additionally, TRAP1-IN-1's structure and pharmacological properties are designed to optimize its bioavailability and efficacy. As research progresses, the understanding of its mechanism of action and potential side effects will be crucial for its development as a therapeutic agent. Overall, TRAP1-IN-1 represents a promising avenue for targeted cancer therapies, particularly in tumors that exhibit dysregulated mitochondrial function.

TRAP1-IN-1

3031102-94-7: TRAP1-IN-1, identified by its CAS number 3031102-94-7, is a small molecule inhibitor that targets the mitochondrial chaperone TRAP1 (tumor necrosis factor receptor-associated protein 1). This compound is of interest in cancer research due to its potential role in modulating mitochondrial function and influencing cellular stress responses. TRAP1 is implicated in various cellular processes, including apoptosis and metabolism, making TRAP1-IN-1 a candidate for therapeutic applications in cancer treatment. The compound is characterized by its ability to selectively inhibit TRAP1 activity, which may lead to altered mitochondrial dynamics and enhanced sensitivity of cancer cells to chemotherapeutic agents. Additionally, TRAP1-IN-1's structure and pharmacological properties are designed to optimize its bioavailability and efficacy. As research progresses, the understanding of its mechanism of action and potential side effects will be crucial for its development as a therapeutic agent. Overall, TRAP1-IN-1 represents a promising avenue for targeted cancer therapies, particularly in tumors that exhibit dysregulated mitochondrial function.

<p>TRAP1-IN-1 is a selective TRAP1 inhibitor, induces degradation of TRAP1 downstream proteins, inhibits OXPHOS, and disrupts mitochondrial membrane potential.</p>

CAS 3031102-94-7

TRAP1-IN-1

TRAP1-IN-1

Ref: TM-T79285